Rabeprazole
Rabeprazole, a benzimidazole proton pump inhibitor similar to omeprazole and lansoprazole, has been approved by the FDA for treatment of duodenal ulcers, healing and maintenance treatment of erosive or ulcerative gastroesophageal reflux disease, and for long-term treatment of chronic hypersecretory conditions, including Zollinger-Ellison syndrome...
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Rabeprazole
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1066
Article Code: 1066b
Date: November 19, 1999
Volume: 41
Pages: 110-112
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1066
Article Code: 1066b
Date: November 19, 1999
Volume: 41
Pages: 110-112
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)